In this issue:
Fertility preservation in women undergoing allogeneic SCT
Leukaemia selection
First-line ibrutinib and venetoclax for CLL
Ibrutinib ±rituximab in CLL
Updated results for ibrutinib, bendamustine and rituximab in relapsed CLL/SLL
Haploidentical vs. unrelated allogeneic SCT for relapsed/ refractory AML
Lenalidomide + azacitidine for relapsed AML after allogeneic SCT
Lymphoma selection
6 vs. 8 rituximab doses in aggressive B-cell lymphoma
Improving CNS relapse prediction in DLBCL
First-line bendamustine + rituximab in indolent non- Hodgkin’s or mantle-cell lymphoma
PET-adapted therapy after 3 ABVD cycles in any-stage Hodgkin’s lymphoma
High-dose chemotherapy with autologous SCT in PCNSL
Please login below to download this issue (PDF)